Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2014-10-14 Earnings Release
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Stabil försäljning för OLYSIO under tredje kvartalet 2014
Earnings Release Classification · 95% confidence The document is a press release titled "Stabil försäljning för OLYSIO under tredje kvartalet 2014" (Stable sales for OLYSIO during the third quarter of 2014). It provides key financial highlights for Q3 2014, specifically focusing on net sales figures and royalty calculations. Crucially, the text states: "Medivir kommer att publicera sin rapport för det tredje kvartalet den 20 november klockan 08.30 CET efterföljt ett konferenssamtal för investerare..." (Medivir will publish its report for the third quarter on November 20th...). This indicates the document itself is an announcement about upcoming results, not the full quarterly report (IR) or the earnings release (ER) which usually contains the full results. Since it announces the publication of the Q3 report and a subsequent conference call, it functions as a preliminary announcement or a regulatory filing related to the upcoming release. Given the content is a summary of preliminary results and an announcement of the full report publication date, it most closely aligns with an Earnings Release (ER) which is the initial announcement of periodical financial results (key highlights only). However, the text explicitly states the *full report* will be published later, making it a precursor. In many contexts, such a preliminary release containing key figures before the full filing is classified as an Earnings Release (ER). If it were purely an announcement of the *date* of the report without figures, it would be RPA. Since it contains Q3 sales figures, ER is the best fit among the specific financial categories. Q3 2014
2014-10-14 Swedish
Start av fas II-studien IMPACT för utvärdering av Simeprevir i kombination med Sofosbuvir och Daclatasvir vid behandling av hepatit C- patienter
Regulatory Filings Classification · 89% confidence The document is a press release from Medivir AB announcing that its partner, Janssen, has started patient recruitment for a Phase II clinical trial (IMPACT study) evaluating the drug Simeprevir in combination with other agents for Hepatitis C treatment. This type of announcement, detailing clinical trial progress, drug development updates, and partnership activities, is characteristic of investor relations communications. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a formal audit report (AR). Since it is a specific announcement about clinical development and partnership progress, it fits best under the general category of Investor Relations or a specific announcement type. Given the options, this is a specific corporate update related to R&D and partnerships. It is not a Director's Dealing (DIRS), a Dividend Notice (DIV), or a Capital Change (CAP). It is most closely related to general corporate news that would be disseminated to investors. Since there isn't a specific 'Clinical Trial Update' code, and it is a formal announcement disseminated to the market, it falls under the broad category of Regulatory Filings (RNS) as a general corporate announcement, or potentially Investor Presentation (IP) if it were a slide deck, but it reads like a news release. Given the nature of the content (announcing a clinical trial start), it is a significant corporate event announcement. In the absence of a specific R&D code, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for a press release detailing operational/clinical progress, although it could also be argued as a type of Investor Information. However, RNS serves as the best catch-all for non-standard, material corporate news releases.
2014-10-10 Swedish
Phase II IMPACT study initiated to evaluate Simeprevir in combination with Sofosbuvir and Daclatasvir to treat genotype 1 and 4 hepatitis C patients
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing that its partner, Janssen, has initiated a Phase II clinical study (IMPACT) for a combination drug therapy (simeprevir, sofosbuvir, daclatasvir) for Hepatitis C. This type of announcement, detailing clinical trial progress, partnership updates, and product development news, is characteristic of an Investor Relations (IR) communication, often released via regulatory channels. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific legal/governance filing, it fits best under the general category for investor-focused news that isn't a formal financial statement or presentation. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate announcement of this nature, although 'LTR' (Legal Proceedings Report) or 'CAP' (Capital/Financing Update) are less relevant. However, since it is a specific corporate update about a clinical trial milestone, and not a general regulatory filing, I will re-evaluate. This is a standard corporate press release providing operational/pipeline updates to investors. In many databases, such announcements fall under 'Regulatory Filings' (RNS) if they don't fit a more specific operational category. Since there is no specific category for 'Clinical Trial Updates' or 'Press Releases', RNS serves as the best general regulatory/corporate announcement category.
2014-10-10 English
Medivir presenterar data från Cathepsin S-hämmarprogrammet, inklusive MIV-247, för behandling av neuropatisk smärta vid 15th World Congress on Pain
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing that they are presenting preclinical data for their drug candidate MIV-247 at the 15th World Congress on Pain. It details the scientific findings, the significance of the data, and provides contact information. This type of announcement, focusing on scientific updates, clinical trial progress, or presentation of data at conferences, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or often falls under a general regulatory/investor communication category. Since it is an announcement *about* data being presented, and not a formal financial report (like 10-K, IR, ER), nor a specific management/board change, it best fits the category for detailed investor-focused material or a general regulatory announcement. Given the focus on scientific progress and investor relations context, 'Investor Presentation (IP)' is a strong candidate if the content were the slides, but as a press release detailing scientific progress, it is often categorized as a general regulatory filing or an investor-focused release. However, looking at the definitions, it is not a formal financial report, nor a management change, nor a dividend notice. It is an update on R&D progress. Since there isn't a specific 'R&D Update' code, and it is a formal announcement intended for investors regarding company progress, it aligns closely with the nature of an Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the detailed nature of the scientific update, it leans towards IP, but as a press release, RNS is also plausible. Since it is a detailed update on a specific drug program intended for investors, I will classify it as Investor Presentation (IP), as it serves the function of presenting key company progress to the investment community, even if it's via a press release format rather than the actual slides.
2014-10-09 Swedish
Medivir to present data from its Cathepsin S inhibitor program including MIV-247 for neuropathic pain, at the 15th World Congress on Pain
Regulatory Filings Classification · 90% confidence The document is a press release from Medivir AB announcing that data from its drug development program (MIV-247) will be presented at an external medical conference (15th World Congress on Pain). It details the scientific findings and the context of the presentation, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement related to investor/scientific communication. Since it is an announcement about scientific data presentation rather than a formal financial report, and it doesn't fit the specific categories like DIRS, DIV, or CAP, it falls best under the general 'Regulatory Filings' (RNS) category as a general corporate/investor communication, or potentially an Investor Presentation (IP) if it were the presentation itself, but here it is the *announcement* of the presentation. Given the options, RNS serves as the best general regulatory/corporate announcement fallback for non-standard disclosures.
2014-10-09 English
Medivir Capital Markets Meeting on 16 October 2014
Investor Presentation Classification · 95% confidence The document is a short announcement from Medivir regarding an upcoming 'Capital Markets Meeting' scheduled for October 16, 2014. It details the time, venue, and purpose (CEO update on strategy and capital structure), and provides registration instructions. Since this is an announcement about an event where strategy and capital structure will be discussed, it strongly relates to investor relations and strategic updates. Given the options, 'Investor Presentation' (IP) is the closest fit for materials presented at such a meeting, but the document itself is the *announcement* of the meeting, not the presentation content. However, the content discussed (strategy and capital structure) is highly relevant to investor materials. Since there is no specific code for 'Meeting Announcement', I must choose the best fit based on the subject matter. The discussion of 'strategy and capital structure' aligns well with the content typically found in an Investor Presentation (IP). Alternatively, it could be seen as a general regulatory announcement (RNS) or a general update. Given the focus on strategy and capital structure for investors/analysts, IP is the most contextually relevant classification for the *topic* being announced. However, applying the 'MENU VS MEAL' rule: this is an announcement of an event, not the presentation itself. If the event were a standard earnings call, it would be CT. Since it's a Capital Markets Meeting focused on strategy, it's an investor-facing event. If the document were longer and contained the presentation slides, IP would be correct. As a short announcement, it functions as a general update. Given the specific focus on strategy and capital structure, and the lack of a dedicated 'Meeting Announcement' code, I will classify it as an Investor Presentation (IP) as it directly relates to the material to be presented, or RNS as a general announcement. Given the high specificity of the categories, and the focus on strategy/capital structure, IP is a strong candidate for the *type* of information being disseminated, even if this specific document is just the invitation. If the document were purely administrative, RNS would be better. Since it outlines the core topics for investors, IP is chosen, but with moderate confidence due to the document being an invitation rather than the presentation itself. Re-evaluating: The document is purely an invitation/logistical announcement for an event where strategy will be discussed. This is a general corporate announcement. RNS (Regulatory Filings / General regulatory announcements) is the most appropriate fallback for an announcement that doesn't fit the specific report types (like ER, IR, 10-K) or specific event types (like DIV, DVA).
2014-10-07 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.